ABSTRACT
Background and Objectives Establishing the etiology of community-acquired pneumonia (CAP) in children at admission is challenging. As a result, most children receive antibiotics that do not need.
This study aims to build and validate a diagnostic tool combining clinical, analytical and radiographical features to sequentially differentiate viral from bacterial CAP, and among bacterial CAP, typical from atypical bacteria, to improve choice of treatment.
Methods Consecutive hospitalized children between 1 month and 16 years of age with CAP were enrolled. An extensive microbiological workup was performed. A score was built with a training set of 70% patients, to first differentiate between viral and bacterial CAP and secondly, typical from atypical bacterial CAP. To select variables, a Ridge model was used. Optimal cut-off points were selected to maximize specificity setting a high sensitivity (80%). Weights of each variable were calculated with a multivariable logistic regression. The score was validated with the rest of the participants.
Results In total, 262 (53%) children (median age, 2 years, 52.3% male) had an etiological diagnosis.
The step 1 discriminates viral from bacterial CAP. Bacterial CAPs were classified with a sensitivity=97%, a specificity=48%, and a ROC’s area under the curve (AUC)=0.81. If a CAP was classificated as bacterial, it was assessed with step 2. The step 2 differentiates typical vs. atypical bacterial CAP. Typical bacteria were classified with a sensitivity=100%, a specificity=64%, and AUC=0.90.
Conclusion This two-steps tool can facilitate the physician’s decision to prescribe antibiotics without compromising patient safety.
Article summary We validated a clinical tool to predict the aetiology of CAP in children safely. This tool differentiates CAP into viral, atypical bacteria and typical bacteria.
“What’s Known on This Subject”Establishing the aetiology of community-acquired pneumonia (CAP) in children at admission is challenging. As a result, most admitted children with CAP receive antibiotics.
“What This Study Adds”We validated a clinical tool to predict the aetiology of pneumonia in children safely, differentiating among viral, atypical bacteria and typical bacteria.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) and cofounded by the European Regional Development Funds [PI17/01458] - Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS) Grant for emerging groups [PCAPE 2011_0025, Registry 320/11] - Instituto de Investigacion Hospital 12 de Octubre (i+12) [AY191212-1] - Universidad Europea de Madrid [2017/UEM03]. TS was funded by the Spanish Ministry of Health - Instituto de Salud Carlos III (ISCIII) and co- funded by the European Union (FEDER) [Contratos Juan Rodes, Grant JR16/00021] The funders/sponsors did not participate in the work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Boards of Hospital Universitario Ramon y Cajal (first phase, code 2011/0025) and Hospital 12 de Octubre (second phase, code 17/311) and the other participating hospitals.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This work was supported by the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) and cofounded by the European Regional Development Funds [PI17/01458] -
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Grant for emerging groups [PCAPE 2011_0025, Registry 320/11] - Instituto de Investigación Hospital 12 de Octubre (i+12) [AY191212-1] - Universidad Europea de Madrid [2017/UEM03].
TS was funded by the Spanish Ministry of Health - Instituto de Salud Carlos III (ISCIII) and co- funded by the European Union (FEDER) [Contratos Juan Rodés, Grant JR16/00021] The funders/sponsors did not participate in the work
Conflicts of interest: The authors have no conflicts of interest relevant to this article to disclose
Data Availability
On request after consideration
Abbreviatures
- ADV
- Adenovirus
- AUC
- Area under the curve
- CAP
- Community-acquired pneumonia
- CoV
- Coronavirus
- CRP
- C-reactiva protein
- CXR
- Chest X-ray
- EV
- Enterovirus
- hBoV
- Human Bocavirus
- hMPV
- Human Metapneumovirus
- NPA
- Nasopharyngeal aspirate
- PCV
- pneumococcal conjugate vaccine
- PIV
- Parainfluenza virus
- PCR
- Polymerase Chain Reaction
- PCT
- Procalcitonin
- ROC
- Receiver Operator Curve
- RhV
- Rhinovirus
- RSV
- Respiratory Syncitial Virus
- WoB
- work of breathing
